Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer

about

Tissue miR-193b as a Novel Biomarker for Patients with Ovarian Cancer.CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways.Nuclear Export Inhibition for Pancreatic Cancer Therapy.

P2860

Q36395243-A5BFF0BB-9FBE-42FA-B8CD-C498BA6730C5 Q37330941-4630405B-A921-4123-8D8E-A857ECCC2BC0 Q55040338-76CC77F3-0291-4DAB-B863-86ADAEF8D7BC

P2860

Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer

Item

http://www.wikidata.org/entity/Q35732942

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer

@ast

Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer

@en

type

Item

label

Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer

@ast

Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer

@en

prefLabel

Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer

@ast

Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer

@en

P1476

Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer

@en

P2093

Huize Liu

http://www.w3.org/2001/XMLSchema#string

Mingshan Niu

http://www.w3.org/2001/XMLSchema#string

Xuejiao Liu

http://www.w3.org/2001/XMLSchema#string

Yan Han

http://www.w3.org/2001/XMLSchema#string

Yulong Chong

http://www.w3.org/2001/XMLSchema#string

P2860

Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1

Integrated genomic analyses of ovarian carcinoma

Atomic basis of CRM1-cargo recognition, release and inhibition

RSF1 is a positive regulator of NF-κB-induced gene expression required for ovarian cancer chemoresistance.

Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents

SINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agents

Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells

Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer.

Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma.

High-grade serous ovarian cancer arises from fallopian tube in a mouse model.

P2888

s13048-015-0166-y

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13048-015-0166-Y

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

278046857

http://www.w3.org/2001/XMLSchema#string

P6179

1047792117

http://www.w3.org/2001/XMLSchema#string

P698

26055813

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

4465006

http://www.w3.org/2001/XMLSchema#string

Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer

about

P2860

P2860

Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P6179

P698

P921

P932